Emerging Novel Therapeutics in Triple-Negative Breast Cancer. Review uri icon

Overview

abstract

  • The mortality from breast cancer has steadily decreased due in part to early detection and advances in therapy. The treatment options for breast cancer vary considerably depending on the histological subtype. There are a number of very effective targeted therapies available for estrogen receptor-positive disease and for human epidermal growth factor receptor 2-positive disease. However, triple-negative breast cancer is a particularly aggressive subtype. This subtype represents an unmet need for improved therapies. TNBC is a heterogenous subtype of breast cancer that is beginning to be refined by its molecular characteristics and clinical response to a targeted therapeutic approach. Here we review the recent advances in the treatment of TNBC with emphasis on the many emerging novel targeted therapies.

publication date

  • January 1, 2019

Research

keywords

  • Molecular Targeted Therapy
  • Triple Negative Breast Neoplasms

Identity

Scopus Document Identifier

  • 85071743255

Digital Object Identifier (DOI)

  • 10.1007/978-3-030-20301-6_20

PubMed ID

  • 31456195

Additional Document Info

volume

  • 1152